Han Soo Yoo

Han Soo Yoo

Auto-generated profile, based on publicly available information

Han Soo Yoo

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
SCSeok Jong Chung
Seok Jong Chung
HYHan Soo Yoo
Han Soo Yoo
JOJungsu S. Oh
Jungsu S. Oh
JKJae Seung Kim
Jae Seung Kim
BYByoung Seok Ye
Byoung Seok Ye
PLPhil Hyu Lee
Phil Hyu Lee

21 June 2018 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
HYHan Soo Yoo
Han Soo Yoo
SJSeun Jeon
Seun Jeon
SCSeok Jong Chung
Seok Jong Chung
MYMijin Yun
Mijin Yun
PLPhil Hyu Lee
Phil Hyu Lee
BYByoung Seok Ye
Byoung Seok Ye

19 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYang Hyun Lee
Yang Hyun Lee
JCJungho Cha
Jungho Cha
SCSeok Jong Chung
Seok Jong Chung
HYHan Soo Yoo
Han Soo Yoo
YSYoung H. Sohn
Young H. Sohn
PLPhil Hyu Lee
Phil Hyu Lee
This study aimed to investigate the potential beneficial effects of estrogen on nigrostriatal dopaminergic neuron degeneration in postmenopausal drug-naïve Parkinson’s disease (PD). Based on the ratio of lifetime estrogen exposure length to the total length of the estrogen exposure and deprivation period, postmenopausal women with drug-naïve PD were divided into low (n = 31) and high (n = 31) estrogen exposure ratio groups. We performed a comparative analysis of the striatal dopamine transporter (DAT) availability between the two groups. Additionally, we evaluated the longitudinal change in the levodopa equivalent dose per month using a linear mixed model. The motor symptoms were more severe in the low estrogen exposure ratio group than in the high estrogen exposure ratio group (P = 0.016). PD patients in the two groups had significantly lower DAT availability on all striatal sub-regions except for ventral striatum than did age- and sex-matched normal controls. When comparing the two groups, PD patients in the low estrogen exposure ratio group exhibited significantly lower DAT availability in the posterior putamen (P = 0.024) and in the ventral putamen (P = 0.036) than those in the high estrogen exposure ratio group. The estimated monthly levodopa equivalent dose changes were 10.9 in the low estrogen exposure ratio group and 7.1 in the high estrogen exposure ratio group with a significant interaction between the two groups (P = 0.001). These in vivo data provide indirect evidence showing that estrogen may elicit a beneficial effect on nigrostriatal dopamine neurons in PD.

14 May 2019 in Human Brain Mapping
Verified
Journal Article
Closed access
PDF file
SCSeok Jong Chung
Seok Jong Chung
HYHan Soo Yoo
Han Soo Yoo
YLYang Hyun Lee
Yang Hyun Lee
HLHye Sun Lee
Hye Sun Lee
BYByoung Seok Ye
Byoung Seok Ye
PLPhil Hyu Lee
Phil Hyu Lee

1 July 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
SCSeok Jong Chung
Seok Jong Chung
SJSeun Jeon
Seun Jeon
HYHan Soo Yoo
Han Soo Yoo
GKGyuri Kim
Gyuri Kim
JOJungsu S. Oh
Jungsu S. Oh
PLPhil Hyu Lee
Phil Hyu Lee

18 December 2018 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
SCSeok Jong Chung
Seok Jong Chung
YPYeong‐Hun Park
Yeong‐Hun Park
HYHyuk Jin Yun
Hyuk Jin Yun
HKHunki Kwon
Hunki Kwon
HYHan Soo Yoo
Han Soo Yoo
PLPhil Hyu Lee
Phil Hyu Lee
Background and purpose: To clarify whether subtyping of amnestic and non‐amnestic mild cognitive impairment (MCI) is clinically relevant in Parkinson's disease (PD) by analyzing patterns of neuroimaging and longitudinal cognitive changes.Methods: We performed comparative analyses of cortical thickness, hippocampal volume, white matter integrity and resting‐state functional connectivity between the patients with de‐novo PD with amnestic MCI (PD‐aMCI) (n = 50) and non‐amnestic MCI (PD‐naMCI) (n = 50) subtypes. Additionally, we assessed the longitudinal rate of cognitive decline in each cognitive domain over time and the rate of dementia conversion in patients with de‐novo PD‐aMCI (n = 125) and PD‐naMCI (n = 61).Results: The demographic data showed that scores in memory domains were lower in the PD‐aMCI group compared with the PD‐naMCI group. There were no significant differences in cortical thickness, hippocampal volume and white matter integrity between the two groups, although the PD‐aMCI group exhibited more cortical thinning and hippocampal atrophy relative to the control group. The PD‐aMCI group exhibited increased functional connectivity in the left posterior parietal region with the salience network relative to the PD‐naMCI group. The longitudinal cognitive assessment demonstrated that patients with PD‐aMCI exhibited a more rapid cognitive decline in frontal/executive function than those with PD‐naMCI (P = 0.022). In addition, the PD‐aMCI group had a higher risk of dementia conversion than the PD‐naMCI group.Conclusions: This study suggests that the designation of PD‐MCI subtypes based on memory function would highlight the heterogeneity of functional correlates as well as the longitudinal cognitive prognosis.